← Back to Search

Smoke-Free Home Program for Smoking Cessation

N/A
Recruiting
Led By Maya Vijayaraghavan, MD, MAS
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 years or older
Ability to understand study procedures and to comply with them for the entire length of the study
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial will examine the impact of a smoke-free home intervention on reducing tobacco-caused disparities among 400 homeless residents in 20 sites across the San Francisco Bay Area.

Who is the study for?
This trial is for English-speaking adults who currently smoke in their homes, have smoked at least 100 cigarettes in their lifetime, and are living in permanent supportive housing. They should expect to stay there for at least a year and be able to follow the study's procedures.Check my eligibility
What is being tested?
The study tests a smoke-free home intervention that includes resident counseling and staff training. It aims to encourage voluntary adoption of smoke-free homes among residents of permanent supportive housing sites across the San Francisco Bay Area.See study design
What are the potential side effects?
Since this trial involves behavioral interventions like counseling and education rather than medications, traditional side effects are not expected. However, participants may experience stress or discomfort discussing smoking habits.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I understand and can follow the study's procedures.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of participants who adopt a smoke-free home voluntarily
Secondary outcome measures
Proportion of participants who achieve abstinence

Trial Design

2Treatment groups
Experimental Treatment
Group I: Wait-List Control (Usual Care) then crossover to Smoke-free home PSH resident interventionExperimental Treatment1 Intervention
The current standard of care includes no interventions for smoke-free home adoption or referrals to smoking cessation resources. Wait-list group receives Smoke-Free Home (SFH) intervention after intervention group complete 6-month follow-up
Group II: Smoke-free home permanent supportive housing (PSH) resident intervention + Staff InterventionExperimental Treatment2 Interventions
Study staff will deliver a one hour, one-on-one counseling to PSH residents that includes: (1) a step-by-step guide on how to voluntarily adopt a smoke-free home, (2) information on second hand smoke (SHS) and third-hand smoke, alternative combustible tobacco and nicotine product use, cannabis-tobacco co-use, effects of SHS on kids and pets,(3) a worksheet on calculating personal costs related to tobacco use, and (4) pledges to designate one's home smoke-free. At follow-up assessments, the study team will ask participants whether they had a chance to view the intervention materials in between visits and will offer an opportunity for participants to discuss conflicts that they had experienced around smoke-free home adoption and will provide strategies to address these roadblocks.

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,505 Previous Clinical Trials
15,237,155 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,664 Previous Clinical Trials
40,925,605 Total Patients Enrolled
Maya Vijayaraghavan, MD, MASPrincipal InvestigatorUniversity of California, San Francisco
1 Previous Clinical Trials
83 Total Patients Enrolled

Media Library

Resident counselling Clinical Trial Eligibility Overview. Trial Name: NCT04855357 — N/A
Smoking Cessation Research Study Groups: Smoke-free home permanent supportive housing (PSH) resident intervention + Staff Intervention, Wait-List Control (Usual Care) then crossover to Smoke-free home PSH resident intervention
Smoking Cessation Clinical Trial 2023: Resident counselling Highlights & Side Effects. Trial Name: NCT04855357 — N/A
Resident counselling 2023 Treatment Timeline for Medical Study. Trial Name: NCT04855357 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals have been recruited for this research project?

"Affirmative. The details available on clinicaltrials.gov confirm that this study is actively seeking participants, with the initial posting occuring on January 24 2022 and the most recent update being February 22nd 2022. 400 people need to be enrolled from 1 medical facility."

Answered by AI

Are opportunities for participation in this study still available?

"Affirmative. According to clinicaltrials.gov, enrollment is ongoing in this study which was first made public on January 24th 2022 and recently revised on February 22nd 2022."

Answered by AI

Who else is applying?

What site did they apply to?
University of California, San Francisco
What portion of applicants met pre-screening criteria?
Met criteria

Why did patients apply to this trial?

I want to quit smoking but don't know where to start.
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Smoke-free Home Intervention in Permanent Supportive Housing
2022. "Smoke-free Home Intervention in Permanent Supportive Housing". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04855357.
~40 spots leftby Jul 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top